Drugs / ADI-270
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06480565 | Dec 2024 → Jun 2026 overdue | clear cell renal carcinoma | Adicet Therapeutics | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-07-08 | Adicet Therapeutics | Regulatory Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma adicetbio.com ↗
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-270 for the potential treatment of patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) who have been treated with an immune checkpoint inhibitor and a vascular endothelial growth factor inhibitor. |
| 2024-06-24 | Adicet Therapeutics | Regulatory Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma adicetbio.com ↗
the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to evaluate ADI-270 |
| 2024-04-22 | Adicet Therapeutics | Results Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting adicetbio.com ↗
Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models |
| 2023-05-18 | Adicet Therapeutics | Results Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting adicetbio.com ↗
In this study, gamma delta T cells modified to express CD70 CAR were successfully generated and expanded without evident hindrances from CD70-mediated fratricide in the process. |
All press releases naming this drug 9 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADI-270 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06480565 ↗ |
| Modality | Cell therapy | “an allogeneic γδ CAR-T cell product” PMID 40592738 ↗ Jul 2025 |
| Target | CD70 | “an allogeneic γδ CAR-T cell product targeting CD70+ cancers” PMID 40592738 ↗ Jul 2025 |